Renal Cell Cancer Update

Dr Joseph Mikhael from the Translational Genomics Research Institute in Phoenix, Arizona, discusses agents that have been recently approved for the treatment of multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNewAgentsMM21).

Dr Zofia Piotrowska from the Massachusetts General Hospital in Boston discusses emerging strategies for patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEGFRExon20NSCLC21).

Dr Mark Pegram from the Stanford University School of Medicine discusses the latest clinical data on and optimal use of newly approved therapies for HER2-positive metastatic breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2MetastaticBC21).

Dr Shaji Kumar from the Mayo Clinic in Rochester, Minnesota, and Dr Philip Thompson from the University of Texas MD Anderson Cancer Center discuss the role of minimal residual disease assessment in the management of multiple myeloma and chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMRD21).

Dr Justin Gainor from the Massachusetts General Hospital in Boston discusses emerging targets in non-small cell lung cancer. CME and select publications here (http://www.researchtopractice.com/OncologyTodayNewTargetsNSCLC21).

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville discusses the latest clinical data on and optimal management of ER-positive metastatic breast cancer. CME and select publications here (http://www.researchtopractice.com/OncologyTodayERPositivemBC21).

Dr Ann LaCasce from the Dana-Farber Cancer Institute discusses key presentations on chronic lymphocytic leukemia and follicular lymphoma from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHLymphomaCLL21/Issue1).

Dr Kathleen Moore from the University of Oklahoma Health Sciences Center discusses key 2020 presentations on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySGOPARP21).

Dr Steven Coutre from Stanford Medicine in California discusses recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia.  CME information and select publications here (http://www.researchtopractice.com/OncologyTodayFrontLineCLL21).

Dr Aaron Gerds from the Cleveland Clinic Taussig Cancer Institute discusses key presentations on myeloproliferative neoplasms from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHAML21).

Dr Matthew Galsky from the Icahn School of Medicine at Mount Sinai in New York discusses recently published and emerging data on newly approved agents for urothelial bladder carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayUBCNovelAgents21)

Dr Corey Langer from the Abramson Cancer Center at the University of Pennsylvania discusses recently published and emerging data on the role of immune checkpoint inhibitors in the treatment of metastatic non-small cell lung cancer without actionable mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCWT21)

Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discusses the role of PARP inhibition in the management of ovarian cancer.  CME information and select publications here (http://www.researchtopractice.com/OncologyTodayASCOOvarian20)

Dr Sagar Lonial from the Winship Cancer Institute in Atlanta, Georgia, discuses key presentations on the management of multiple myeloma from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMM20)

Dr David Quinn from the University of Southern California in Los Angeles discusses the impact of COVID-19 on the management of cancer and the current challenges he is experiencing as a physician caring for patients at the front line of the pandemic. Additional resources * Lee LYW et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020;395(10241):1919-26. Abstract (https://pubmed.ncbi.nlm.nih.gov/32473682/) * Malek AE et al. Cancer and COVID-19. Lancet 2020;396(10257):1066-7. Abstract (https://pubmed.ncbi.nlm.nih.gov/33038963/) * Poortmans P et al. Cancer and COVID-19: What do we really know? Lancet 2020;395(10241):1884-5. Abstract (https://pubmed.ncbi.nlm.nih.gov/32479827/) * Xia Y et al. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e180. Abstract (https://pubmed.ncbi.nlm.nih.gov/32142622/) * Yang F et al. Clinical characteristics and outcomes of cancer patients with COVID-19. _J Med Virol _2020;92(10):20

Dr Marjorie Zauderer from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research in the management of mesothelioma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMesothelioma20).

Dr Stephen Liu from Georgetown University Hospital in Washington, DC, discusses recently published and emerging research on the role of immunotherapy combination approaches in the treatment of metastatic non-small cell lung cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayNSCLCWT20).

Dr Hope Rugo discusses the role of PARP inhibitors in the treatment of breast cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).

Dr Ursula Matulonis discusses the role of PARP inhibitors in the treatment of ovarian cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).

Dr Philip A Philip discusses the role of PARP inhibitors in the treatment of pancreatic cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).